Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.136
Neutral
RSI(14)
50.222
Neutral
STOCH(KDJ)(9,3,3)
46.202
Buy
ATR(14)
0.282
High Vlolatility
CCI(14)
-63.443
Neutral
Williams %R
57.669
Sell
TRIX(12,20)
0.065
Sell
StochRSI(14)
79.289
Buy
Orchestra Biomed Holdings Inc
OBIO4.410USD
+0.060+1.38%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
249.01MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Orchestra Biomed Holdings Inc
Currency: USD Updated: 2025-12-22Key Insights
Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 114/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.33.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Orchestra Biomed Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.333
Target Price
+203.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Orchestra Biomed Holdings Inc Highlights
StrengthsRisks
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.64M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.64M.
Overvalued
The company’s latest PE is -2.46, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.17M shares, decreasing 0.76% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 380.51K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.02.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Orchestra Biomed Holdings Inc is 5.81, ranking 189/208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 861.00K, representing a year-over-year decrease of 12.77%, while its net profit experienced a year-over-year decrease of 35.02%.
Score
Financials
7.33
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.13
Operational Efficiency
2.83
Growth Potential
4.67
Shareholder Returns
7.07
Orchestra Biomed Holdings Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Orchestra Biomed Holdings Inc is 8.38, ranking 24/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.46, which is -47.70% below the recent high of -1.28 and -573.58% above the recent low of -16.54.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 114/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00, ranking 59/208 in the Healthcare Equipment & Supplies industry. The average price target for Orchestra Biomed Holdings Inc is 12.00, with a high of 20.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.333
Target Price
+203.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
90
Total
4
Median
7
Average
Company name
Ratings
Analysts
Orchestra Biomed Holdings Inc
OBIO
7
Boston Scientific Corp
BSX
36
Veeva Systems Inc
VEEV
34
Intuitive Surgical Inc
ISRG
34
Edwards Lifesciences Corp
EW
34
Thermo Fisher Scientific Inc
TMO
27
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Orchestra Biomed Holdings Inc is 5.16, ranking 184/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 5.20 and the support level at 3.84, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.372
Buy
MA10
4.411
Sell
MA20
4.647
Sell
MA50
4.207
Buy
MA100
3.419
Buy
MA200
3.291
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Orchestra Biomed Holdings Inc is 3.00, ranking 135/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 35.54%, representing a quarter-over-quarter decrease of 40.51%. The largest institutional shareholder is The Vanguard, holding a total of 1.48M shares, representing 2.62% of shares outstanding, with 23.11% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
RTW Investments L.P.
Medtronic PLC
Perceptive Advisors LLC
HSAC 2 Holdings LLC
Knoll Capital Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Orchestra Biomed Holdings Inc is 3.07, ranking 131/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.62
VaR
+7.67%
240-Day Maximum Drawdown
+60.70%
240-Day Volatility
+94.18%
Return
Best Daily Return
60 days
+17.47%
120 days
+17.47%
5 years
+58.09%
Worst Daily Return
60 days
-9.78%
120 days
-20.26%
5 years
-24.30%
Sharpe Ratio
60 days
+3.23
120 days
+1.59
5 years
+0.18
Risk Assessment
Maximum Drawdown
240 days
+60.70%
3 years
+89.40%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.35
3 years
-0.19
5 years
-0.12
Skewness
240 days
-0.03
3 years
+1.53
5 years
+1.86
Volatility
Realised Volatility
240 days
+94.18%
5 years
--
Standardised True Range
240 days
+6.82%
5 years
+20.94%
Downside Risk-Adjusted Return
120 days
+254.99%
240 days
+254.99%
Maximum Daily Upside Volatility
60 days
+71.13%
Maximum Daily Downside Volatility
60 days
+45.00%
Liquidity
Average Turnover Rate
60 days
+0.92%
120 days
+1.04%
5 years
--
Turnover Deviation
20 days
+202.35%
60 days
+117.15%
120 days
+146.25%
Peer Comparison
Healthcare Equipment & Supplies
Orchestra Biomed Holdings Inc
OBIO
5.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Orchestra Biomed Holdings Inc?
The TradingKey Stock Score provides a comprehensive assessment of Orchestra Biomed Holdings Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Orchestra Biomed Holdings Inc’s performance and outlook.
How do we generate the financial health score of Orchestra Biomed Holdings Inc?
To generate the financial health score of Orchestra Biomed Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Orchestra Biomed Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Orchestra Biomed Holdings Inc.
How do we generate the company valuation score of Orchestra Biomed Holdings Inc?
To generate the company valuation score of Orchestra Biomed Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Orchestra Biomed Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Orchestra Biomed Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Orchestra Biomed Holdings Inc.
How do we generate the earnings forecast score of Orchestra Biomed Holdings Inc?
To calculate the earnings forecast score of Orchestra Biomed Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Orchestra Biomed Holdings Inc’s future.
How do we generate the price momentum score of Orchestra Biomed Holdings Inc?
When generating the price momentum score for Orchestra Biomed Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Orchestra Biomed Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Orchestra Biomed Holdings Inc.
How do we generate the institutional confidence score of Orchestra Biomed Holdings Inc?
To generate the institutional confidence score of Orchestra Biomed Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Orchestra Biomed Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Orchestra Biomed Holdings Inc.
How do we generate the risk management score of Orchestra Biomed Holdings Inc?
To assess the risk management score of Orchestra Biomed Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Orchestra Biomed Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Orchestra Biomed Holdings Inc.
